Chronic lobe collapse: another bronchiectasis phenotype or a marker of Pseudomonas colonisation?

O. Munteanu (Chisihau, Republic of Moldova)

Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Munteanu (Chisihau, Republic of Moldova). Chronic lobe collapse: another bronchiectasis phenotype or a marker of Pseudomonas colonisation?. 4065

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis
Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017
Year: 2017

A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015

Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors?
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016

Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013

Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016

Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections
Source: Eur Respir J 2012; 40: 227-238
Year: 2012

A single isolation of pseudomonas aeruginosa predicts poor quality of life and increased exacerbation frequency in adult bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015

Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics
Source: Eur Respir J 2001; 18: Suppl. 33, 540s
Year: 2001

Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis
Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017
Year: 2018

Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006

Lung function, symptoms and inflammatory biomarkers in patients with bronchiectasis (brx) with and without chronic pseudomonas aeruginosa (psa) colonisation
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009

The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis
Source: Eur Respir J 2006; 28: 974-979
Year: 2006

Early re-colonization with pseudomonas aeruginosa (PA) after treatment: a possible risk factor for development of chronic infection in cystic fibrosis (CF) patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008

Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung
Source: Eur Respir J , 49 (4)  1602108; DOI: 10.1183/13993003.02108-2016
Year: 2017

Impact of Pseudomonas aeruginosa on exacerbation and death in patients with chronic obstructive pulmonary disease.
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003

Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
Source: International Congress 2017 – Update on community acquired pneumonia
Year: 2017

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013